Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,670.00
-220.00 (-3.74%)
Jan 19, 2026, 3:30 PM KST
-26.60%
Market Cap544.53B
Revenue (ttm)1.96B
Net Income (ttm)-21.96B
Shares Out96.04M
EPS (ttm)-183.47
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,940,509
Average Volume645,393
Open6,090.00
Previous Close5,890.00
Day's Range5,480.00 - 6,140.00
52-Week Range4,325.00 - 7,940.00
Beta0.06
RSI60.28
Earnings DateMar 18, 2026

About Hyundai Bioscience

Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2000
Employees 69
Stock Exchange KOSDAQ
Ticker Symbol 048410
Full Company Profile

Financial Performance

In 2024, Hyundai Bioscience's revenue was 15.05 billion, an increase of 58.73% compared to the previous year's 9.48 billion. Losses were -6.93 billion, -52.21% less than in 2023.

Financial Statements

News

There is no news available yet.